Bank of Montreal Can Reduces Stock Holdings in Enovis Co. (NYSE:ENOV)

Bank of Montreal Can lessened its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 83.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,615 shares of the company's stock after selling 32,543 shares during the period. Bank of Montreal Can's holdings in Enovis were worth $290,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ENOV. Aster Capital Management DIFC Ltd bought a new stake in shares of Enovis in the 4th quarter worth $29,000. Quadrant Capital Group LLC boosted its stake in shares of Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Enovis by 8.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 330,817 shares of the company's stock worth $14,516,000 after buying an additional 25,619 shares during the last quarter. Pitcairn Co. boosted its stake in shares of Enovis by 46.2% in the 4th quarter. Pitcairn Co. now owns 11,673 shares of the company's stock worth $512,000 after buying an additional 3,690 shares during the last quarter. Finally, ExodusPoint Capital Management LP boosted its stake in shares of Enovis by 919.4% in the 4th quarter. ExodusPoint Capital Management LP now owns 333,302 shares of the company's stock worth $14,625,000 after buying an additional 300,605 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Stock Performance

NYSE ENOV traded down $0.28 on Tuesday, hitting $34.38. 21,750 shares of the company traded hands, compared to its average volume of 750,424. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -15.68 and a beta of 1.86. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The business's 50 day moving average price is $36.51 and its 200-day moving average price is $42.00. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $56.43.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Equities analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.